Zura Bio Ltd Logo

Zura Bio Ltd

Developing novel dual-pathway therapies for severe autoimmune and inflammatory conditions.

ZURA | US

Overview

Corporate Details

ISIN(s):
KYG507521071 (+1 more)
LEI:
Country:
United States of America
Address:
4225 EXECUTIVE SQUARE, 92037 LA JOLLA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company focused on developing novel medicines for severe autoimmune and inflammatory conditions. The company's approach centers on dual-pathway biology, aiming to create transformative therapies for patients underserved by single-pathway treatments. Its development portfolio includes several therapeutic candidates, notably tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio is focused on demonstrating the efficacy, safety, and dosing convenience of its assets to significantly improve patient well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Zura Bio Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zura Bio Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zura Bio Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

TALPHERA, INC. Logo
Develops therapies for acute pain and anticoagulants for medically supervised settings.
United States of America
TLPH
Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
Tarsus Pharmaceuticals, Inc. Logo
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
United States of America
TARS
TAUNS Laboratories, Inc. Logo
Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.
Japan
197A
Taysha Gene Therapies, Inc. Logo
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
Tchaikapharma High Quality Medicines AD Logo
Develops and makes affordable generic drugs for cardiovascular & metabolic diseases.
Bulgaria
THQM
TDSPHARM Co., Ltd. Logo
Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.
South Korea
464280
Tectonic Therapeutic, Inc. Logo
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
Tego Science, Inc. Logo
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea
191420
Develops radiopharmaceuticals that use targeted radiation to image and treat various cancers.
United States of America
TLX

Talk to a Data Expert

Have a question? We'll get back to you promptly.